[Overdosing on diltiazem in heptic insufficiency]

Area of Science:

• Cardiology
• Pharmacology
• Hepatology

Background:

• Diltiazem is a calcium channel blocker commonly prescribed for cardiovascular conditions like unstable angina.
• Hepatic function significantly influences drug metabolism and clearance, potentially altering drug efficacy and safety profiles.
• Atrioventricular conduction abnormalities can arise from various factors, including medication side effects.

Observation:

• A middle-grade hepatic failure patient experienced unexpected atrioventricular conduction disturbances while on standard-dose diltiazem therapy for unstable angina.
• This specific adverse drug event was not previously reported in medical literature or product information.

Findings:

• Diltiazem administration in the presence of hepatic dysfunction can lead to unforeseen complications affecting cardiac conduction.
• The pharmacokinetic properties of diltiazem suggest an increased risk of adverse effects when liver function is compromised.

Implications:

• Clinicians should exercise caution when prescribing diltiazem to patients with hepatic impairment.
• Further investigation is warranted to understand the precise mechanisms and incidence of diltiazem-induced conduction abnormalities in liver disease.
• This case underscores the importance of considering organ-specific function in drug safety assessments.